Cardiovascular risk factors and lifetime risk estimation in hiv-infected patients under antiretroviral treatment in Spain

HIV Clinical Trials

Volumn 16, Issue 2, 2015, Pages 57-65

  Estrada, Vicente ^a   Bernardino, José Ignacio ^b   Masiá, Mar ^c   Iribarren, José Antonio ^d   Ortega, Alejandra ^a   Lozano, Fernando ^e   Miralles, Celia ^f   Olalla, Julián ^g   Santos, Jesuś ^h   Elıás, Marıá Jesuś Pérez ⁱ   Domingo, Pere ^j   Cruz, Arturo Fernández ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^d HOSPITAL DONOSTIA   (Spain)

^e HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^f UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

^g HOSPITAL COSTA DEL SOL   (Spain)

^h HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

ⁱ HOSPITAL RAMÓN Y CAJAL   (Spain)

^j HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

more..

Author keywords

Antiretroviral treatment; Cardiovascular disease; Cardiovascular risk factors; HIV; Lifetime cardiovascular risk

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTIRETROVIRUS AGENT;

ABDOMINAL OBESITY; ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR DISEASE ASSESSMENT; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CORONARY RISK; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; FRAMINGHAM RISK SCORE; GROUPS BY AGE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MIXED INFECTION; MULTICENTER STUDY; PREVALENCE; PRIORITY JOURNAL; REGICOR RISK SCORE; RISK ASSESSMENT; SCORING SYSTEM; SMOKING; SOCIAL STATUS; SPAIN; TIME TO TREATMENT; VIRUS LOAD; CLINICAL TRIAL; COMPLICATION; RISK FACTOR;

ADULT; AGED; ANTI-RETROVIRAL AGENTS; CARDIOVASCULAR DISEASES; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; FEMALE; HIV INFECTIONS; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS; SPAIN; TOBACCO SMOKING;

EID: 84983631381     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1179/1528433614Z.0000000008     Document Type: Article

References (26)

1. Palella FJ Jr, Phair JP. Cardiovascular disease in HIV infection. Curr Opin HIV AIDS. 2011;6:266–271
2. Duprez DA, Neuhaus J, Kuller LH, et al. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One. 2012;7:e44454
3. Friis-Moller N, Thiebaut R, Reiss P, et al. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil. 2010;17:491–501
4. D’Agostino RB Sr. Cardiovascular risk estimation in 2012: lessons learned and applicability to the HIV population. J Infect Dis. 2012;205(Suppl 3):S362–S367
5. Berry JD, Dyer A, Cai X, et al. Lifetime risks of cardiovascular disease. N Engl J Med. 2012;366:321–329
6. Masia M, Perez-Cachafeiro S, Leyes M, et al. Riesgo cardiovascular en pacientes con infeccioń por el virus de la inmunodeficiencia humana en Espanã. Cohorte CoRIS, 2011. Enferm Infecc Microbiol Clin. 2012;30:517–527
7. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III), JAMA. 2001; 285:2486–2497
8. Grau M, Marrugat J. Funciones de riesgo en la prevencioń primaria de las enfermedades cardiovasculares. Rev Esp Cardiol. 2008;61:404–416
9. Petr EJ, Ayers CR, Pandey A, et al. Perceived lifetime risk for cardiovascular disease (from the Dallas Heart Study). Am J Cardiol. 2014;114:53–58
10. Catalina-Romero C, Sainz Gutierrez JC, Quevedo AL, et al. Prevalencia de consumo de tabaco en poblacioń trabajadora tras la entrada en vigor de la Ley 42/2010. Rev Esp Salud Publica. 2012;86:177–188
11. Martinez E, Arribas J, López-Aldeguer J. Factors associated with a high cardiovascular risk in HIV infected patients in Spain: a multicenter, nationwide, cross sectional study. Paper presented at: 12th Conference on Retrovirus and Opportunistic Infections; February 22–25, 2005; Boston, MA, USA. Abs # 870
12. Jerico C, Knobel H, Sorli ML, Montero M, Guelar A, Pedro-Botet J. Prevalencia de factores de riesgo cardiovascular en pacientes con infeccioń por el VIH. Rev Clin Esp. 2006;206: 556–559
13. Garcia-Lazaro M, Rivero RA, Camacho EA, et al. Variabilidad en la valoracioń del riesgo coronario en pacientes infectados por el virus de la inmunodeficiencia humana. Med Clin (Barc). 2007;129:521–524
14. Franco M, Cooper R, Bilal U, Fuster V. Control of coronary heart disease risk factors and evidence-based therapies: joint efforts for coronary heart disease prevention in Spain. Rev Esp Cardiol. 2011;64:962–964
15. Huber M, Ledergerber B, Sauter R, et al. Outcome of smoking cessation counselling of HIV-positive persons by HIV care physicians. HIV Med. 2012;13:387–397
16. Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123:2292–2333
17. Worm SW, Kamara DA, Reiss P, et al. Elevated triglycerides and risk of myocardial infarction in HIV-positive persons. AIDS. 2011;25:1497–1504
18. Freiberg MS, Leaf DA, Goulet JL, et al. The association between the receipt of lipid lowering therapy and HIV status among veterans who met NCEP/ATP III criteria for the receipt of lipid lowering medication. J Gen Intern Med. 2009;24: 334–340
19. Reinsch N, Neuhaus K, Esser S, et al. Are HIV patients undertreated? Cardiovascular risk factors in HIV: results of the HIV-HEART study. Eur J Prev Cardiol. 2012;19:267–274
20. Ahmed MH, Al-Atta A, Hamad MA. The safety and effectiveness of statins as treatment for HIV-dyslipidemia: the evidence so far and the future challenges. Expert Opin Pharmacother. 2012;13:1901–1909
21. Berry JD, Liu K, Folsom AR, et al. Prevalence and progression of subclinical atherosclerosis in younger adults with low shortterm but high lifetime estimated risk for cardiovascular disease: the coronary artery risk development in young adults study and multi-ethnic study of atherosclerosis. Circulation. 2009;119: 382–389
22. Hulten E, Villines TC, Cheezum MK, et al. Calcium score, coronary artery disease extent and severity, and clinical outcomes among low Framingham risk patients with low vs high lifetime risk: results from the CONFIRM registry. J Nucl Cardiol. 2014; 21:29–37
23. Marma AK, Lloyd-Jones DM. Systematic examination of the updated Framingham heart study general cardiovascular risk profile. Circulation. 2009;120:384–390
24. Ferreira-Gonzalez I. The epidemiology of coronary heart disease. Rev Esp Cardiol. 2014;67:139–144
25. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al 2013 ACC/ AHA Guideline on the Assessment of Cardiovascular Risk: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Supp 2):S49–73
26. Nakagawa F, Lodwick RK, Smith CJ, et al. Projected life expectancy of people with HIV according to timing of diagnosis. AIDS. 2012;26:335–343.